Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
作者： Meng Wang , Jing Zhao , Lian-Min Zhang , Hui Li , Jin-Pu Yu
DOI: 10.1007/S00432-012-1291-2
关键词: Mutation 、 Oncology 、 Lung cancer 、 Cancer research 、 Epidermal growth factor 、 Cetuximab 、 Erlotinib 、 Internal medicine 、 T790M 、 Tyrosine-kinase inhibitor 、 Medicine 、 Receptor
摘要: Purpose Non-small-cell lung cancer (NSCLC) cells with somatic mutations in epidermal growth factor receptors (EGFR) are initially susceptible to tyrosine kinase inhibitor (TKI); however, eventually resistance TKI is developed these cells, which leads the failure of treatment. The most common mechanism this acquired drug development a secondary T790M mutation EGFR. In study, we investigated effects combination Erlotinib and Cetuximab on L858R lines (H1975), primary NSCLC TKI-resistant EGFR human tumor xenograft model (H1975).
springer.com
sci-hub.se 参考文章(41)
Andrew J Barker, Keith H Gibson, Walter Grundy, Andrew A Godfrey, Jeffrey J Barlow, Mark P Healy, James R Woodburn, Susan E Ashton, Brenda J Curry, Lynn Scarlett, Lianne Henthorn, Laura Richards, Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic & Medicinal Chemistry Letters. ,vol. 11, pp. 1911- 1914 ,(2001) , 10.1016/S0960-894X(01)00344-4
Susumu Kobayashi, Hongbin Ji, Yuki Yuza, Matthew Meyerson, Kwok-Kin Wong, Daniel G. Tenen, Balázs Halmos, An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Research. ,vol. 65, pp. 7096- 7101 ,(2005) , 10.1158/0008-5472.CAN-05-1346
Philipp Steiner, Christopher Joynes, Rajiv Bassi, Su Wang, James R. Tonra, Yaron R. Hadari, Daniel J. Hicklin, Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clinical Cancer Research. ,vol. 13, pp. 1540- 1551 ,(2007) , 10.1158/1078-0432.CCR-06-1887
William Pao, Juliann Chmielecki, Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer Nature Reviews Cancer. ,vol. 10, pp. 760- 774 ,(2010) , 10.1038/NRC2947
Takashi Karashima, Daniel J. Hicklin, Paul Sweeney, Sun Jin Kim, Colin P Dinney, Daniel Kedar, Taro Shuin, Joel W. Slaton, Curtis A Pettaway, Zhen Fan, Jonathan I. Izawa, Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice Clinical Cancer Research. ,vol. 8, pp. 1253- 1264 ,(2002)
Xuewu Zhang, Jodi Gureasko, Kui Shen, Philip A. Cole, John Kuriyan, An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor Cell. ,vol. 125, pp. 1137- 1149 ,(2006) , 10.1016/J.CELL.2006.05.013
David Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas Lynch, Bruce E. Johnson, Vincent A. Miller, Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 28, pp. 357- 360 ,(2010) , 10.1200/JCO.2009.24.7049
Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Yoshitsugu Horio, Toyoaki Hida, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Takashi Takahashi, Yasushi Yatabe, Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence Journal of Clinical Oncology. ,vol. 23, pp. 2513- 2520 ,(2005) , 10.1200/JCO.2005.00.992
Tim Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays Journal of Immunological Methods. ,vol. 65, pp. 55- 63 ,(1983) , 10.1016/0022-1759(83)90303-4
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149